NEW YORK, NY / ACCESSWIRE / May 27, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed on behalf of Vivint Solar, Inc. shareholders (“Vivint” or the “Company”) (NYSE: VSLR) against certain officers of SunEdison Inc. (“SunEdison”). The class action, filed in United States District Court, Eastern District of Missouri, and docketed under 16-cv-00628, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Vivint securities between July 20, 2015 and March 7, 2016 inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

If you are a shareholder who purchased Vivint securities during the Class Period, you have until July 5, 2016 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased. Click here to join this action.

Vivint is a provider of distributed solar energy, which is electricity generated by a solar energy system installed at a customer’s location, including residential, commercial and industrial properties throughout the United States. In July 2015, SunEdison and Vivint announced a merger pursuant to which SunEdison would acquire Vivint. On this announcement, Vivint’s stock price increased $4.87, an increase of approximately 44.8%, to close at $15.75. On February 24, 2016, at the Company’s special shareholders meeting, Vivint shareholders voted to approve the merger with SunEdison.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) SunEdison would be unable to obtain financing for the acquisition of Vivint; (ii) SunEdison’s liquidity was less than Defendants had stated; (iii) SunEdison would not be able to complete the acquisition of Vivint; and (iv) as a result, Defendants’ statements about the merger between SunEdison and Vivint were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On February 29, 2016, after the market closed, SunEdison filed a Notification of Late Filing on Form 12b-25 with the SEC, disclosing that the Company would be unable to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2015. The Notification of Late Filing included information that in late 2015, former SunEdison executives had made allegations concerning the accuracy of SunEdison’s financial position.

On this news, shares of Vivint fell $1.37 per share or over 17% from the stock’s previous closing price to close at $6.52 per share on March 1, 2016, damaging investors.

On March 2, 2016, during trading hours, The Wall Street Journal published an article entitled, “SunEdison’s Takeover of Vivint Solar in Jeopardy as Banks Balk” stating that the Vivint-SunEdison merger was in jeopardy.

On this news, shares of Vivint fell $1.63 per share or 25% from the stock’s previous closing price to close at $4.89 per share on March 2, 2016, damaging investors.

On March 8, 2016, Vivint announced that it was terminating the Merger Agreement. Also on March 8, 2016, Vivint filed a lawsuit against SunEdison in Delaware Chancery Court alleging breach of contract.

On this news, shares of Vivint fell $1.04 per share or approximately 20% from the stock’s previous closing price to close at $5.21 per share on March 7, 2016, damaging investors.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 440503

TORONTO, ON / ACCESSWIRE / May 27, 2016 / Theralase Technologies Inc. (“Theralase®” or the “Company“) (TSXV: TLT) (OTC: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs“) to destroy cancer, announced today that for the three-month period ended March 31, 2016, total revenue increased from $369,136 to $411,448 for the same period in 2015, an 11% increase.

In Canada, revenue decreased 47% to $180,069 from $344,351, in the US, revenue increased 1,720% to $152,375 from $8,369 and international revenue increased 407% to $79,004 from $15,584. The decrease in Canadian revenue in 1Q2016 and the corresponding increase in US and international revenue is attributable to the Company systematically building its sales and marketing teams in the Canadian and US market and the learning curves associated with training and developing a new sales force.

With the recent TLC-2000 FDA 510(k) clearance and Health Canada approval, Theralase is focusing on recruiting a high performing sales and marketing team in Canada and the US with the mandate of dramatically increasing sales of the TLC-2000 across Canada and the United States in 2016. Once these strategic markets have been established and running independently, Theralase will focus on growing its international revenues through exclusive international distribution agreements.

Cost of sales for the three-month period ended March 31, 2016 was $131,764 (32% of revenue) resulting in a gross margin of $279,684 or 68% of revenue, compared to a cost of sales of $135,156 (37% of revenue) in 2015, resulting in a gross margin of $233,148 or 63% of revenue. Cost of sales is represented by the following costs: raw materials, subcontracting, direct and indirect labour and the applicable share of manufacturing overhead.

Selling and marketing expenses for the three-month period ended March 31, 2016 were $316,254 representing 76% of sales, compared with $184,488 or 50% in 2015. The increase is primarily due to increased spending in marketing and sales personnel, which will augment sales in future financial quarters with the launch of the TLC-2000. Selling expenses are expected to continue to increase in the future as the Company expands in Canada, the US and international markets. On-going investment in sales personnel, marketing events and advertising are necessary expenses to generate and increase revenues in subsequent financial quarters.

Administrative expenses for the three-month period ended March 31, 2016 were $623,314 representing a 36% increase from $456,123 in 2015. Increases in administrative expenses were attributable to the following:

• General and administrative expenses increased 17% due to increased spending on investor relations and research scientist activities
• Stock based compensation increased by 110% as a result of vesting of stock options to certain employees, directors and officers of the Company in Q22015
• Administrative salaries increased by 58% as a result of hiring clinical and educational staff.

Research and development expenses totaled $477,588 for the three-month period ended March 31, 2016 compared to $545,645 in 2015 (12% decrease). Research and development expenses represented 34% of the Company’s operating expenses for the period and represent direct investment into the research and development expenses of the TLC-3000 anti-cancer technology.

The net loss for the three-month period ended March 31, 2016 was $1,145,739, which included $171,878 of net non-cash expenses (amortization, stock-based compensation expense, foreign exchange gain/loss and lease inducements). This compared to a net loss for the same period in 2015 of $933,643 which included $165,531 of net non-cash expenses. The PDT division represented $840,449 of this loss (73%). The increase in net loss is due to increased investment in research and development of the TLC-3000, sales, marketing and administrative personnel, all related to the launch of the next generation TLC-2000 therapeutic medical laser system and the commencement of a Phase Ib clinical study for Non-Muscle Invasive Bladder Cancer (“NMIBC“).

Theralase has been very successful in executing on its strategic objectives in 2015 and 1Q2016 by successfully completing:

1. Health Canada Medical Device Licence (Class III) approval of its next generation TLC-2000 Therapeutic Medical Laser System
2. US Food and Drug Administration (“FDA“) 510(k) clearance of the TLC-2000
3. Health Canada Clinical Trial Application (“CTA“) approval
4. Princess Margaret Cancer Centre, University Health Network (“UHN“) Research Ethics Board (“REB“) approval
5. 6 month accelerated stability and 9 month long term stability of it lead anti-cancer PDC TLD-1433
6. A Clinical Research Agreement (“CRA“) with UHN to conduct a Phase Ib clinical study for the indication of NMIBC

Theralase is currently completing sterilization, biocompatibility and mechanical testing of the TLC-3200 medical laser probes used to activate TLD-1433 that has absorbed into bladder cancer lesions and submit the information to Health Canada, via an Investigational Testing Authorization (“ITA”) mid-June 2016 for approval on or about the end of June 2016.

Health Canada requires information and testing that supports:

1. Biocompatibility (the materials that enter the body are proven not harmful to tissue)
2. Mechanical testing (the materials demonstrate the characteristics of functional reliability, tensile strength and repeatability of operation)
3. Sterility (the materials that enter the body are demonstrated to be sterile)

Pending ITA approval from Health Canada, Theralase and UHN will immediately commence enrollment of patients inflicted with NMIBC into a Phase Ib clinical trial.

The Phase Ib NMIBC clinical study protocol will commence by instilling a low dose of TLD-1433 drug into the bladders of three (3) patients with subsequent light activation using the TLC-3200 medical laser. These three (3) patients will then be monitored for thirty (30) days to ensure safety and tolerability of the procedure. If no adverse events are reported, then an additional six (6) patients will be enrolled at a high dose, followed by light activation and follow-up monitoring for six (6) months.

The Phase Ib NMIBC clinical trial will evaluate TLD-1433 for the primary endpoints of safety and tolerability, with a secondary endpoint of pharmacokinetics (where the PDC accumulates in the body and how it exits the body) and an exploratory endpoint of efficacy in a patient population defined by UHN uro-oncology department to enable drug approval.

If safety and tolerability of the procedure is demonstrated in these nine (9) patients, the Phase Ib study results will support Health Canada approval and a Phase IIb multi-center efficacy study for NMIBC will be commenced in Canada, the United States and Europe.

Mr. Dumoulin-White concluded that, “The Company has successfully executed on the majority of its strategic initiatives in 2015 and 1Q2016 and is anticipating ITA approval in or around the end of June 2016 to allow an immediate commencement of a Phase Ib clinical study for NMIBC, which will allow the Company to dramatically increase shareholder value in 2016 by demonstrating the safety, tolerability and as an exploratory outcome measure efficacy of next generation anti-cancer technology.”

About Theralase Technologies Inc.

Theralase Technologies Inc. (“Theralase®” or the “Company“) (TSXV: TLT) (OTC: TLTFF) in its Therapeutic Laser Technology (“TLT“) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT“) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs“), which are able to localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at www.theralase.com and www.sedar.com.

This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Roger Dumoulin-White
President & CEO
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com

SOURCE: Theralase Technologies Inc.

ReleaseID: 440502

SHENZHEN, CHINA / ACCESSWIRE / May 27, 2016 / China Nepstar Chain Drugstore Ltd. (NYSE: NPD) will host a conference call to discuss the results of the first quarter 2016, to be held Tuesday, May 31, 2016 at 8:00 AM Eastern Time.

To participate in this event, dial 877-407- 9210 domestically, or 201-689-8049 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at http://www.nepstar.cn.

If you are unable to participate during the live webcast, the event archive will be available at http://www.nepstar.cn.

You may access the teleconference replay by dialing 877-660-6853 domestically or 201-612-7415 internationally, referencing conference ID # 13638451. The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern on July 7, 2016.

About China Nepstar Chain Drugstore Ltd.

China Nepstar Chain Drugstore Ltd. (NPD) is a leading retail drugstore chain in China. As of December 31, 2015, the Company had 1,998 directly operated stores across 70 cities, one headquarter distribution center and 15 regional distribution centers in China. Nepstar uses directly operated stores, centralized procurement and a network of distribution centers to provide its customers with high-quality, professional and convenient pharmaceutical products and services and a wide variety of other merchandise, including OTC drugs, nutritional supplements, herbal products, personal care products, family care products, and convenience products. Nepstar’s strategy of centralized procurement, competitive pricing, customer loyalty programs and private label offerings has enabled it to capitalize on the continuing economic growth in China and take advantage of the demographic trend in China to achieve a strong brand and leading market position. For further information, please go to http://www.nepstar.cn.

SOURCE: Investor Calendar

ReleaseID: 440441

HALIFAX, NOVA SCOTIA / ACCESSWIRE / May 27, 2016 / Metalo Manufacturing Inc. (CSE: MMI) (formerly Muskrat Minerals Incorporated) announced today that it has filed its unaudited consolidated financial statements and management discussion and analysis for the third quarter ended March 31, 2016. Both are available under the Corporation’s profile on SEDAR at www.sedar.com and on its website at www.metalo.ca.

ABOUT METALO MANUFACTURING INC. (CSE: MMI)

Metalo’s principal focus is an investment in the development and construction of a pig iron manufacturing plant to produce high purity pig iron for steel mills and foundries. MMI is a 44.34% shareholder of Grand River Ironsands Incorporated (“GRI”). GRI owns a 60% interest in North Atlantic Iron Corporation (“NAIC”). NAIC’s business emphasis is to build the plant for the manufacturing of pig iron. NAIC also owns mining rights for an iron ore resource in Happy-Valley- Goose Bay, Newfoundland and Labrador. Additionally, Forks Specialty Metals Inc. (“FSM”) is a wholly-owned subsidiary of GRI and it owns and operates three smelting furnaces in Pennsylvania, USA. FSM is currently used as a testing facility for iron smelting. The Corporation has 17,307,039 issued and outstanding common shares.

Neither CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

The Corporation seeks Safe Harbour.

For additional information contact:

Liz MacKenzie, Corporate Communications (902) 233-7255
info@metalo.ca

(NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION VIA U.S. NEWSWIRE)

SOURCE: Metalo Manufacturing Inc.

ReleaseID: 440501

NEW YORK, NY / ACCESSWIRE / May 27, 2016 / Pomerantz LLP is investigating claims on behalf of investors of Alibaba Group Holdings Limited (“Alibaba”) (NYSE: BABA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

[Click here to join a class action]

The investigation concerns whether Alibaba and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On May 24, 2016, post-market, Alibaba filed an Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (“SEC”) announcing the Company’s financial and operating results for fiscal year 2016. In its Annual Report, Alibaba disclosed that the SEC had requested information relating to “consolidation policies and practices (including [the Company’s] accounting for Cainiao Network as an equity method investee”) and “policies and practices applicable to related party transactions in general, and [the Company’s] reporting of operating data from Singles Day” (a popular online shopping holiday in China).

On this news, Alibaba stock has fallen as much as $4.24, or 5.23%, to $76.88 during intraday trading on May 25, 2016.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

SOURCE: Pomerantz LLP

ReleaseID: 440500

NEW YORK, NY / ACCESSWIRE / May 27, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against Alere Inc. (“Alere” or the “Company”) (NYSE: ALR) and certain of its officers. The class action, filed in United States District Court, District of Massachusetts, and docketed under 16-cv-10834, is on behalf of a class consisting of all persons or entities who purchased Alere securities between May 9, 2013 and April 20, 2016 inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

If you are a shareholder who purchased Alere securities during the Class Period, you have until June 20, 2016 to seek appointment as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased. Click here to join this action.

Alere provides diagnostic tests for infectious disease, cardiometabolic disease, and toxicology.

On February 1, 2016, Alere disclosed that it had entered into a merger agreement with Abbot Laboratories. On this news, Alere’s stock price climbed $16.91, more than 45%, to close at $54.11 per share on February 1, 2016.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about Alere’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Alere improperly recognized and reported revenue in violation of Generally Accepted Accounting Principles; (ii) Alere’s quarterly and annual SEC filings would thus be delayed; (iii) therefore, Alere’s planned merger with Abbott Laboratories would be thrown into doubt; (iv) Alere lacked adequate internal controls over accounting and financial reporting; and (v) consequently, Alere’s financial statements, as well as Defendants’ statements about Alere’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

On February 26, 2016, Alere disclosed its inability to timely file its Annual Report for 2015 because it was investigating “certain aspects of revenue recognition in Africa and China” and evaluating “internal controls over financial reporting for the year ended December 31, 2015.” Alere also disclosed that it had received an SEC subpoena on January 14, 2016, seeking “additional information related to sales of products and services to end-users in Africa, as well as revenue recognition” regarding the same.

On this news, Alere stock fell $0.48 to close at $53.30 on February 29, 2016, the next trading day.

On March 15, 2016, Alere disclosed its inability to file its Annual Report for 2015 within the 15-day extension period because the previously disclosed investigation remained ongoing and had expanded in scope. Finally, the Company disclosed that on March 11, 2016, the Company received a subpoena from the U.S. Department of Justice seeking information on “sales, sales practices and dealings with third-parties (including distributors and foreign governmental officials) in Africa, Asia and Latin America and other matters related to the U.S. Foreign Corrupt Practices Act.”

On this news, Alere stock fell $4.14 per share, or 9.2%, to close at $49.32 on March 15, 2016, on unusually heavy volume.

On April 20, 2016, the CEO of Abbott Laboratories, during the company’s quarterly earnings call, would not affirm Abbott Laboratories’ commitment to merge with Alere.

On this news, Alere stock fell $6.11, or 12.3% per share, to close at $43.36 on April 20, 2016, on unusually heavy volume.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 440499

Princeton Nutrients VitaPulse: Recent News Report Now Uncovers the Most Important Facts Every Consumer Must Know; Published by Researched Reviews

PHILADELPHIA, PA / ACCESSWIRE / May 27, 2016 / Important Update: Cindy Walters of Researched Reviews, who is featured in many news publications as a qualified and respected research analyst, now provides the most important resource links shown below. Ryan Vander states, “Researched Reviews is an independent research and review organization and does not work for Princeton Nutrients but receives compensation from them.”

Cindy Walters confirms, “There Is Now a New Ground Breaking Cardiovascular Health Supplement That Has Investigative Journalists Buzzing.”

Access the News Reported Latest Breakthrough Cardiovascular Health Supplement Right Here

Researched Reviews Reports Their Latest Findings: Princeton Nutrients VitaPulse

Researched Reviews posted their latest report regarding VitaPulse by Princeton Nutrients, describing it as one of the most potent Cardiovascular Health supplements available. VitaPulse includes the Super Antioxidants N-A-C, PQQ, and CoQ10, making the product extremely effective.

Researched Reviews takes an in-depth look at this new VitaPulse Healthy Heart supplement to see if it can deliver on its promises to consumers with Mr. Kingston’s Report:

“Shocking New VitaPulse
Report — This May Change Your Mind”

As heart disease takes more and more lives each year, researchers are working hard to find a way to maintain a healthy heart. Princeton Nutrients is taking a unique approach by using three advanced super antioxidants.

Princeton Nutrients has developed VitaPulse with the help of Dr. Arash Bereliani. Dr. Bereliani is a board certified cardiologist who serves as Princeton Nutrients’ Director of Research.

Princeton Nutrients VitaPulse: Consumers Financial Investment (Price)

Researched Reviews specialist Mr. Kingston reports on important VitaPulse pricing information in the report.

Typically the consumers would be billed as follows: Get the Lowest Discount Price For Princeton Nutrients VitaPulse Available Right Here

Research analyst David Kingston reports, “VitaPulse contains the Super antioxidants: N-A-C, PQQ, and CoQ10 to support a healthy heart, cholesterol levels and cardio-circulatory functions. The effectiveness of the supplement VitaPulse and its viability for the general public has been thoroughly researched, and the results of that research are uncovered in the special report.”

“It was previously thought that heart disease was caused by high cholesterol and too much fat in the diet. That is why, for decades, the US government and its associated health organizations recommend low-fat diets for Americans. They believed that only through a reduction of cholesterol could people cut back their risk of heart disease. But new evidence has now shown that not only is some cholesterol absolutely crucial for good heart health but, also, that the root cause of heart disease has been misunderstood for a very long time.”

“Recent studies have shown that heart disease is caused by oxidation. This is a process that harms the cells over time, damaging the heart and creating a buildup of toxins in the arteries. Oxidation can be caused by a number of factors, such as eating too many foods containing harmful cholesterol, Carbohydrates, a lack of nutrients, genetics, age and other factors.”

ALSO SEE: VitaPulse Reviews — What They’ll Never Tell Anyone

VitaPulse contains three active antioxidants that may help improve heart health. Each advanced antioxidant works on unique aspects of cardiovascular health to create a unique combination to help consumers maintain or improve cardiovascular health.

CoQ10 – This powerful antioxidant does more than just get rid of toxins in the body that lead to heart disease. It may also improve metabolism, which may burn away many harmful chemicals in the body.

N-A-C – May help fight back against heart failure and poor circulation with this antioxidant. NAC may stop the LDL or bad cholesterol from oxidizing. When introduced into the body, NAC becomes glutathione, which is essential for heart health. It can even help prevent a lot of the processes that might damage the heart.

PQQ – Not only helps to protect mitochondria from oxidation and toxic effects of amyloid, PQQ is also showing great promise of being able to help stimulate the production of new mitochondria in human tissue. Many people are trying to fight heart disease off even before they reach middle age. PQQ may help minimize stress and may help the heart muscle heal more quickly. It may also provide anti-aging benefits. Some users report PQQ is giving their skin a healthier look while also possibly reducing the effects of aging on the heart muscle itself.

MUST SEE: VitaPulse : “Don’t Buy This Until You See This First”

Mr. Kingston claims, “With these three Super Antioxidants working together, many of the body’s systems can benefit. While VitaPulse is geared toward improving heart heath and strengthening the heart, the power of these natural ingredients may have a wide-ranging effect on the body.”

“The heart may be healthier as it becomes fortified thanks to these powerful antioxidants”

Research analyst Cindy Walters states, “Another benefit of taking VitaPulse may be
increased energy levels.”

“Getting rid of toxins from the body could work wonders on the muscles and energy production of the cells. Some of the ingredients in VitaPulse may actually unlock the full energy-producing potential of the body’s cells, creating more usable energy and may revitalize whoever is taking the supplement. They could possibly feel years younger, exhibiting more endurance and greater resilience to tiredness and soreness.”

The new report also claims: VitaPulse may also help keep undesired weight off. The CoQ10 inside the supplement may even act as a metabolism booster, possibly allowing the body to burn fat quicker. A great metabolism is something that many people lose once they hit their middle age years, but VitaPulse may help get users metabolism back to where it was when they were younger. It shows promise to unlock a lot of the benefits of youth, including possible increased metabolic rate. This may turn fat content into usable energy and could possibly reduce the strain on the heart.

Researched Reviews Report Also Addresses an Important Consumer Question:

– Is VitaPulse a Scam since it is only available online?

Researched Reviews clearly states VitaPulse is not a scam in any way. According to the latest report, VitaPulse has been shown to produce no major negative side effects and should not cause any allergic reactions. That is due to the all-natural ingredients it contains. Every component of the supplement works with the body’s natural processes, helping the heart and the surrounding systems do what they are supposed to do, naturally.

Anyone concerned about taking VitaPulse and how it may react to certain medical conditions or medications should always consult with their doctor first. Anyone with severe digestive problems is advised to seek medical advice before taking any supplement.

Must See: Critical New Info About Princeton Nutrients VitaPulse Is Now In

David Kingston states, “With all supplements, everybody’s body is different. People who are older may not have much of a metabolism and may have more trouble getting rid of toxins that have built up over time. People who are overweight may have to take the supplement for longer periods of time than most people before they start to see serious changes in their heart health.”

“The body’s current condition, as well as genetic factors, dieting and exercise habits, may affect people’s outcomes while using this supplement. While most individuals should experience improvements to their heart health, they are not all likely to see the same results over the same period of time.”

“For the best results, it is recommended that those who take VitaPulse also attempt to eat healthy diets and exercise regularly under a doctor’s supervision. A healthy diet will be one that is high in HDL or heathy cholesterol, which may also help fight heart disease. This will ensure that the supplement is able to offer its very best protection.”

Mr. Kingston also proclaims, “VitaPulse seems to work for many individuals, and the testimonials from those who have taken it, as well as the results from clinical trials, may prove that it is effective and safe. Anyone looking to maintain a healthy heart may benefit by taking VitaPulse every day. It may act as a shield against toxins and oxidation and may assist individuals to live healthier, happier and even possibly longer lives.”

Caution Must Be Used When Purchasing Princeton Nutrients VitaPulse On-Line…

Cindy Walters states, “This supplement should only be purchased through the manufacturer Princeton Nutrients VitaPulse at http://the-official-website.com/vitapulse-order/“

“Even buying Princeton Nutrients VitaPulse through trusted online retailers, like Amazon, is not advised. Certain vendors at Amazon can often sell expired or outdated products under the guise of selling the best version of a product. Buying an expired product would simply be a waste of money and the potency could be greatly diminished.”

Ms. Walters also added, “Only buying directly from the Official Website are consumers backed with the manufacturers 90-day guarantee. Any consumer not satisfied with the product can send what is left of their supply back to the manufacturer and receive a full refund, even for the supplements they have already taken. That is how confident Princeton Nutrients is about their product, and that inspires confidence in consumers to try it out for themselves.”

This Is The Official Princeton Nutrients VitaPulse Website

Ms. Walters states, “Latest reports published now show there is a problem with many cardiovascular health supplements available today. Almost no one is bringing attention to this critical information, but there is a reason for this, as you’re about to learn”…Click Here for the Full Report

About Researched Reviews.com

Researched-Reviews.com is a well-respected public source of information and product Review Company situated in the suburbs of Philadelphia, PA, assisting consumers to find important information concerning specified products and services that will then help individuals determine if those specific products and services are in fact a suitable fit for them.

Researched Reviews reports back on a broad range of both products and services. Researching and reviewing everything from beauty and health care products to services and membership programs that may be popular in the market place at any given time. Researched Reviews remains committed to providing honest and accurate information to consumers at all time.

Media Contact:

David Kingston

Researched Reviews

(215) 357-6785

support@researched-reviews.com

SOURCE: Researched Reviews.com

ReleaseID: 440496

NEW YORK, NY ACCESSWIRE / May 27, 2016 / HealthWarehouse.com, Inc. (OTCQB: HEWA), the only VIPPS accredited online pharmacy licensed in all 50 states, today announced that the company will present at the 5th Annual SeeThruEquity Microcap Investor Conference at Convene on 730 Third Avenue in New York City on May 31, 2016. Please click here for a list of presenting companies.

Each company will be provided with a 30-minute time slot to present to an audience of investors and industry professionals and company management will also be available for one-on-one meetings with institutional investors.

Conference registration: complimentary for qualified investors and equity research analysts.

In order to register as an attendee of the conference, please click HERE.

The company will be presenting on Tuesday, May 31st at 10:30am EST and an audiofile will be available following the presentation at: http://wsw.com/webcast/seethru16/hewa.

About SeeThruEquity

Since the company’s founding in 2011, SeeThruEquity (STE) has been committed to its core mission: providing impactful, high quality research on uncovered and undercovered microcap stocks and hosting investor conferences throughout the year. STE has been able to grow its research universe to over 190 names.

STE conferences are the ultimate event for publicly traded companies with less than $1 billion in market capitalization because it augments the conference experience with the firm’s research which is part of Wall Street consensus and available across industry leading platforms including Thomson First Call, FactSet, S&P CapitalIQ, Yahoo! Finance and Bloomberg to name a select few. STE has hosted 20 investor conferences which have showcased over 350 companies, attracted over 4500 attendees and have included over 1,700 1-on-1 meetings.

For more information please visit www.steconference.com.

About HealthWarehouse.com

HealthWarehouse.com, Inc. (OTCQB: HEWA) is a trusted VIPPS accredited online pharmacy based in Florence, Kentucky. The Company is focused on the growing out-of-pocket prescription market, which will grow to over $80 billion in 2016. With a mission to provide affordable healthcare to every American by focusing on technology that is revolutionizing prescription delivery, HealthWarehouse.com has become the largest VIPPS accredited online pharmacy in the United States.

HealthWarehouse.com is licensed in all 50 states and only sells drugs that are FDA-approved and legal for sale in the United States. Visit HealthWarehouse.com online at http://www.HealthWarehouse.com.

Contact

Mr. Lalit Dhadphale, CEO
lalit@healthwarehouse.com
(859) 444-7341

SOURCE: HealthWarehouse.com, Inc.

ReleaseID: 440495